{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:10:09Z","timestamp":1793387409052,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.biopha.2018.07.110","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T04:47:48Z","timestamp":1532407668000},"page":"1412-1418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["The pleiotropic role of interleukin-17 in atherosclerosis"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-9128","authenticated-orcid":false,"given":"Gamal","family":"Allam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Abdel-Moneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa M.","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.07.110_bib0005","unstructured":"WHO, WHO_cardiovascular diseases (CVDs), Cardiovasc. Dis. (2015) (Fact sheet Updated May 2017), www.who.int\/entity\/mediacentre\/factsheets\/fs317\/en\/-44k."},{"key":"10.1016\/j.biopha.2018.07.110_bib0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.intimp.2018.01.012","article-title":"Th17 immune responses in Brazilian dyslipidemic patients with atherosclerosis","volume":"56","author":"de Menezes Pereira","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive summary: heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2018.07.110_bib0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4172\/2155-9880.1000352","article-title":"Interleukin-18 and atherosclerosis: mediator or biomarker","volume":"5","author":"Mahajan","year":"2014","journal-title":"J. Clin. Exp. Cardiolog."},{"issue":"7","key":"10.1016\/j.biopha.2018.07.110_bib0025","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nri1882","article-title":"The immune response in atherosclerosis: a double-edged sword","volume":"6","author":"Hansson","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0030","article-title":"Regulation of pro-and anti-atherogenic cytokines","author":"Ray","year":"2017","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.biopha.2018.07.110_bib0035","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: a novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2018.07.110_bib0040","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.autrev.2017.07.009","article-title":"Effects of interleukin 17 on the cardiovascular system","volume":"16","author":"Robert","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/cvr\/cvx225","article-title":"IL-17 in atherosclerosis: the good and the bad","volume":"114","author":"Taleb","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13671-018-0210-4","article-title":"Effects of biologic therapy on cardiovascular disease in psoriasis","volume":"7","author":"Henning","year":"2018","journal-title":"Curr. Dermatol. Rep."},{"key":"10.1016\/j.biopha.2018.07.110_bib0060","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2018.07.110_bib0065","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0070","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3908061","article-title":"The role of IL-17 and related cytokines in inflammatory autoimmune diseases","volume":"2017","author":"Kuwabara","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"3","key":"10.1016\/j.biopha.2018.07.110_bib0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","article-title":"IL-17 in chronic inflammation: from discovery to targeting","volume":"22","author":"Beringer","year":"2016","journal-title":"Trends Mol. Med."},{"issue":"15","key":"10.1016\/j.biopha.2018.07.110_bib0080","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.109.924886","article-title":"Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E\u2013deficient mice","volume":"121","author":"Smith","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00395-010-0135-y","article-title":"Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability","volume":"106","author":"Erbel","year":"2011","journal-title":"Basic Res. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0090","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clim.2011.07.003","article-title":"IL-17 induces apoptosis of vascular endothelial cells\u2014a potential mechanism for human acute coronary syndrome","volume":"141","author":"Zhu","year":"2011","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","article-title":"Interleukin 17 promotes angiotensin II\u2013induced hypertension and vascular dysfunction","volume":"55","author":"Madhur","year":"2010","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","article-title":"Functional specialization of interleukin-17 family members","volume":"34","author":"Iwakura","year":"2011","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0105","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028522","article-title":"Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications","volume":"10","author":"Monin","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2018.07.110_bib0110","article-title":"IL-17A facilitates platelet function through the ERK2 signaling pathway in patients with acute coronary syndrome","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.biopha.2018.07.110_bib0115","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.4049\/jimmunol.1400181","article-title":"IL-17A influences essential functions of the monocyte\/macrophage lineage and is involved in advanced murine and human atherosclerosis","volume":"193","author":"Erbel","year":"2014","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2018.07.110_bib0120","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.4049\/jimmunol.1000116","article-title":"A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice","volume":"185","author":"Gao","year":"2010","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2018.07.110_bib0125","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.4049\/jimmunol.0901126","article-title":"Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice","volume":"183","author":"Erbel","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biopha.2018.02.103","article-title":"The potential pathogenic role of IL-17\/Th17 cells in both type 1 and type 2 diabetes mellitus","volume":"101","author":"Abdel-Moneim","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2018.07.110_bib0135","doi-asserted-by":"crossref","first-page":"11627","DOI":"10.1038\/ncomms11627","article-title":"T-bet is a key modulator of IL-23-driven pathogenic CD4+ T cell responses in the intestine","volume":"7","author":"Krausgruber","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000314626","article-title":"Emerging role of IL-17 in atherosclerosis","volume":"2","author":"Chen","year":"2010","journal-title":"J. Innate Immun."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/imr.12036","article-title":"Th17 cell development: from the cradle to the grave","volume":"252","author":"Z\u00fa\u00f1iga","year":"2013","journal-title":"Immunol. Rev."},{"issue":"7090","key":"10.1016\/j.biopha.2018.07.110_bib0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector T H 17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0155","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.immuni.2008.03.003","article-title":"Contextual regulation of inflammation: a duet by transforming growth factor-\u03b2 and interleukin-10","volume":"28","author":"Li","year":"2008","journal-title":"Immunity"},{"issue":"7192","key":"10.1016\/j.biopha.2018.07.110_bib0160","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature06878","article-title":"TGF-\u03b2-induced Foxp3 inhibits T H 17 cell differentiation by antagonizing ROR\u03b3t function","volume":"453","author":"Zhou","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2018.07.110_bib0165","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0170","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6309219","article-title":"Balancing inflammation: the link between Th17 and regulatory T cells","volume":"2016","author":"Diller","year":"2016","journal-title":"Mediators Inflamm."},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.immuni.2008.03.001","article-title":"Th17 cell differentiation: the long and winding road","volume":"28","author":"McGeachy","year":"2008","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.biopha.2018.07.110_bib0180","first-page":"1358","article-title":"The role of cytokines in the development of atherosclerosis","volume":"81","author":"Fatkhullina","year":"2016","journal-title":"Biochem. Mosc. Suppl. Ser. A Membr. Cell Biol. (Mosc)"},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0185","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.atherosclerosis.2007.02.023","article-title":"Atheroprotective role of interleukin-6 in diet-and\/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model","volume":"197","author":"Madan","year":"2008","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/imr.12035","article-title":"The Th17 family: flexibility follows function","volume":"252","author":"Basu","year":"2013","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2018.07.110_bib0195","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs T H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0200","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.12659\/MSM.896355","article-title":"Interleukin-6 (IL-6) receptor antagonist protects against rheumatoid arthritis","volume":"22","author":"Li","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.biopha.2018.07.110_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.02.005","article-title":"Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: the Troms\u00f8 Study","volume":"271","author":"Eltoft","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.biopha.2018.07.110_bib0210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni1439","article-title":"The adaptor Act1 is required for interleukin 17\u2013dependent signaling associated with autoimmune and inflammatory disease","volume":"8","author":"Qian","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0215","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2018.01.032","article-title":"Noncanonical NF-\u03baB signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction","volume":"270","author":"Maracle","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2018.07.110_bib0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2018.01.027","article-title":"Selective inhibition of endothelial NF-\u03baB signaling attenuates chronic intermittent hypoxia-induced atherosclerosis in mice","volume":"270","author":"Song","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2018.07.110_bib0225","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2018.04.018","article-title":"Silencing of Non-POU-domain-containing octamer-binding protein stabilizes atherosclerotic plaque in apolipoprotein E-knockout mice via NF-\u03baB signaling pathway","volume":"263","author":"Zhang","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0230","doi-asserted-by":"crossref","first-page":"234","DOI":"10.25011\/cim.v36i4.19957","article-title":"Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina","volume":"36","author":"Liu","year":"2013","journal-title":"Clin. Invest. Med."},{"key":"10.1016\/j.biopha.2018.07.110_bib0235","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.biopha.2018.02.030","article-title":"MicroRNA signature of regulatory T cells in health and autoimmunity","volume":"100","author":"Soltanzadeh-Yamchi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2018.07.110_bib0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2005.09.006","article-title":"Anti-TNF therapy: where have we got to in 2005?","volume":"25","author":"Feldmann","year":"2005","journal-title":"J. Autoimmun."},{"issue":"18","key":"10.1016\/j.biopha.2018.07.110_bib0245","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and Beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"10.1016\/j.biopha.2018.07.110_bib0250","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1161\/01.CIR.0000125700.33637.B1","article-title":"Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors","volume":"109","author":"W\u00e6hre","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI61163","article-title":"IL-1 and atherosclerosis: a murine twist to an evolving human story","volume":"122","author":"Rader","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.biopha.2018.07.110_bib0260","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2018.07.110_bib0265","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/euhj.2001.2805","article-title":"Plasma tumour necrosis factor-\u03b1 and early carotid atherosclerosis in healthy middle-aged men","volume":"23","author":"Skoog","year":"2002","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.biopha.2018.07.110_bib0270","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.ATV.0000143933.20616.1b","article-title":"Inhibition of tumor necrosis factor-\u03b1 reduces atherosclerosis in apolipoprotein E knockout mice","volume":"24","author":"Br\u00e5n\u00e9n","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"42","key":"10.1016\/j.biopha.2018.07.110_bib0275","doi-asserted-by":"crossref","first-page":"26174","DOI":"10.1074\/jbc.271.42.26174","article-title":"Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55","volume":"271","author":"Schreyer","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2018.07.110_bib0280","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2011-200468","article-title":"Combination of IL-17 and TNF\u03b1 induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells","volume":"71","author":"Hot","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cardiores.2005.04.019","article-title":"Interferon-\u03b3 and atherosclerosis: pro-or anti-atherogenic?","volume":"67","author":"Harvey","year":"2005","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0290","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui","year":"2006","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2018.07.110_bib0295","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.108.827618","article-title":"Interleukin-17 and interferon-\u03b3 are produced concomitantly by human coronary artery\u2013infiltrating T cells and act synergistically on vascular smooth muscle cells","volume":"119","author":"Eid","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0300","doi-asserted-by":"crossref","first-page":"13831","DOI":"10.1038\/s41598-017-14365-1","article-title":"IFN-\u03b3 and TNF-\u03b1 synergism may provide a link between psoriasis and inflammatory atherogenesis","volume":"7","author":"Mehta","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0305","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1189\/jlb.1113571","article-title":"Implications of chemokines, chemokine receptors, and inflammatory lipids in atherosclerosis","volume":"95","author":"Rolin","year":"2014","journal-title":"J. Leukoc. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2018.07.110_bib0310","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.2538","article-title":"Atherosclerosis: current pathogenesis and therapeutic options","volume":"17","author":"Weber","year":"2011","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.biopha.2018.07.110_bib0315","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2174\/0929867324666170419150614","article-title":"The impact of IL-17 in atherosclerosis","volume":"24","author":"Lu","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0320","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4062\/biomolther.2010.18.2.135","article-title":"Interleukin-4, oxidative stress, vascular inflammation and atherosclerosis","volume":"18","author":"Lee","year":"2010","journal-title":"Biomol. Ther. (Seoul)"},{"issue":"12","key":"10.1016\/j.biopha.2018.07.110_bib0325","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.acvd.2016.04.002","article-title":"Inflammation in atherosclerosis","volume":"109","author":"Taleb","year":"2016","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"2-6","key":"10.1016\/j.biopha.2018.07.110_bib0330","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1615\/CritRevImmunol.v37.i2-6.30","article-title":"Functions of IL-4 and control of its expression","volume":"37","author":"Brown","year":"2017","journal-title":"Crit. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2018.07.110_bib0335","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.2353\/ajpath.2007.060857","article-title":"Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice","volume":"171","author":"King","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0340","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2018.07.110_bib0345","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.ATV.19.12.2823","article-title":"IL-10: An \"immunologic scalpel\" for atherosclerosis?","volume":"19","author":"Terkeltaub","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2018.07.110_bib0350","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1096\/fj.09-148155","article-title":"Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice","volume":"24","author":"Han","year":"2010","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0355","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIRCRESAHA.108.188243","article-title":"IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR","volume":"104","author":"Krishnamurthy","year":"2009","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.biopha.2018.07.110_bib0360","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1586\/1744666X.2014.971014","article-title":"Immunobiology of IL-37: mechanism of action and clinical perspectives","volume":"10","author":"Quirk","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0365","article-title":"Potential role of IL-37 in atherosclerosis","author":"McCurdy","year":"2017","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.biopha.2018.07.110_bib0370","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1684\/ecn.2011.0288","article-title":"IL-37: a new anti-inflammatory cytokine of the IL-1 family","volume":"22","author":"Boraschi","year":"2011","journal-title":"Eur. Cytokine Netw."},{"issue":"11","key":"10.1016\/j.biopha.2018.07.110_bib0375","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.1944","article-title":"IL-37 is a fundamental inhibitor of innate immunity","volume":"11","author":"Nold","year":"2010","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0380","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41598-017-02987-4","article-title":"Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice","volume":"7","author":"Ji","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2018.07.110_bib0385","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1159\/000487344","article-title":"Transgenic overexpression of IL-37 protects against atherosclerosis and strengthens plaque stability","volume":"45","author":"Liu","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"8","key":"10.1016\/j.biopha.2018.07.110_bib0390","doi-asserted-by":"crossref","first-page":"E1672","DOI":"10.3390\/ijms18081672","article-title":"The effects of selective hematopoietic expression of human IL-37 on systemic inflammation and atherosclerosis in LDLr-Deficient mice","volume":"18","author":"Hoeke","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0395","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/2393-8692.184728","article-title":"Cytokines and other inflammatory mediators in periodontal health and disease","volume":"2","author":"Grover","year":"2016","journal-title":"Indian J. Oral Health Res."},{"issue":"32","key":"10.1016\/j.biopha.2018.07.110_bib0400","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.2174\/092986712803833164","article-title":"Protective role of adiponectin in cardiovascular disease","volume":"19","author":"Shibata","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2018.07.110_bib0405","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.4049\/jimmunol.1001269","article-title":"IL-17 regulates adipogenesis, glucose homeostasis, and obesity","volume":"185","author":"Z\u00fa\u00f1iga","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0410","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ijo.2008.216","article-title":"Increased activity of interleukin-23\/interleukin-17 proinflammatory axis in obese women","volume":"33","author":"Sumarac-Dumanovic","year":"2009","journal-title":"Int. J. Obes."},{"issue":"7","key":"10.1016\/j.biopha.2018.07.110_bib0415","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1007\/s12035-016-0036-7","article-title":"Adiponectin suppresses t helper 17 cell differentiation and limits autoimmune CNS inflammation via the SIRT1\/PPAR\u03b3\/ROR\u03b3t pathway","volume":"54","author":"Zhang","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0420","doi-asserted-by":"crossref","first-page":"31414","DOI":"10.1038\/srep31414","article-title":"Elevated adiponectin levels suppress perivascular and aortic inflammation and prevent AngII-induced advanced abdominal aortic aneurysms","volume":"6","author":"W\u00e5gs\u00e4ter","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2018.07.110_bib0425","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrcardio.2011.62","article-title":"Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets","volume":"8","author":"Lahoute","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2018.07.110_bib0430","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrneph.2017.51","article-title":"The immunology of atherosclerosis","volume":"13","author":"Gister\u00e5","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"issue":"3","key":"10.1016\/j.biopha.2018.07.110_bib0435","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1172\/JCI57175","article-title":"Control of inflammation by integration of environmental cues by regulatory T cells","volume":"123","author":"Chaudhry","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0440","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clim.2008.01.009","article-title":"The Th17\/Treg imbalance in patients with acute coronary syndrome","volume":"127","author":"Cheng","year":"2008","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0445","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cyto.2009.09.007","article-title":"The Th17\/Treg functional imbalance during atherogenesis in ApoE\u2212\/\u2212 mice","volume":"49","author":"Xie","year":"2010","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.biopha.2018.07.110_bib0450","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5551\/jat.31088","article-title":"HMGB1modulates the Treg\/Th17 ratio in atherosclerotic patients","volume":"23","author":"Ding","year":"2016","journal-title":"J. Atheroscler. Thromb."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0455","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/ATVBAHA.114.303567","article-title":"IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles","volume":"35","author":"Taleb","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2018.07.110_bib0460","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/joim.12406","article-title":"Inflammation and plaque vulnerability","volume":"278","author":"Hansson","year":"2015","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0465","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/ATVBAHA.111.229997","article-title":"Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice","volume":"32","author":"Danzaki","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7559","key":"10.1016\/j.biopha.2018.07.110_bib0470","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature14452","article-title":"Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation","volume":"523","author":"Gagliani","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0475","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cvr\/cvx181","article-title":"Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content","volume":"114","author":"Brauner","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"196","key":"10.1016\/j.biopha.2018.07.110_bib0480","doi-asserted-by":"crossref","first-page":"196ra100","DOI":"10.1126\/scitranslmed.3006133","article-title":"Transforming growth factor\u2013\u03b2 signaling in t cells promotes stabilization of atherosclerotic plaques through an Interleukin-17\u2013Dependent pathway","volume":"5","author":"Gister\u00e5","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.biopha.2018.07.110_bib0485","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.it.2011.06.007","article-title":"T helper 17 cell heterogeneity and pathogenicity in autoimmune disease","volume":"32","author":"Ghoreschi","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0490","article-title":"Interleukin 17A in atherosclerosis - Regulation and pathophysiologic effector function","author":"Nordlohne","year":"2017","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0495","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2018.02.074","article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3","volume":"79","author":"Egeberg","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0500","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-015-0143-7","article-title":"Secukinumab: a review in moderate to severe plaque psoriasis","volume":"16","author":"Garnock-Jones","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"issue":"S1","key":"10.1016\/j.biopha.2018.07.110_bib0505","article-title":"Secukinumab reduces endothelial dysfunction in subjects with moderate-to-Severe plaque psoriasis over 52 weeks: results of the exploratory CARIMA study","volume":"2","author":"von Stebut","year":"2018","journal-title":"SKIN J. Cut. Med."},{"issue":"9999","key":"10.1016\/j.biopha.2018.07.110_bib0510","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0515","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40257-017-0254-4","article-title":"Ixekizumab: a review in moderate to severe plaque psoriasis","volume":"18","author":"Syed","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"issue":"14","key":"10.1016\/j.biopha.2018.07.110_bib0520","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2018.07.110_bib0525","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.4049\/jimmunol.175.6.3800","article-title":"ROR\u03b3t recruits steroid receptor coactivators to ensure thymocyte survival","volume":"175","author":"Xie","year":"2005","journal-title":"J. Immunol."},{"issue":"26","key":"10.1016\/j.biopha.2018.07.110_bib0530","doi-asserted-by":"crossref","first-page":"22707","DOI":"10.1074\/jbc.C111.250407","article-title":"Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of ROR\u03b3t protein","volume":"286","author":"Xu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2018.07.110_bib0535","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.biopha.2017.11.032","article-title":"Ursolic acid ameliorates oxidative stress, inflammation and fibrosis in diabetic cardiomyopathy rats","volume":"97","author":"Wang","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2018.07.110_bib0540","doi-asserted-by":"crossref","first-page":"E1101","DOI":"10.3390\/molecules23051101","article-title":"Ursolic acid attenuates atherosclerosis in ApoE\u2212\/\u2212 mice: role of LOX-1 mediated by ROS\/NF-\u03baB pathway","volume":"23","author":"Li","year":"2018","journal-title":"Molecules"},{"issue":"7344","key":"10.1016\/j.biopha.2018.07.110_bib0545","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature09978","article-title":"Digoxin and its derivatives suppress T H 17 cell differentiation by antagonizing ROR\u03b3t activity","volume":"472","author":"Huh","year":"2011","journal-title":"Nature"},{"issue":"7344","key":"10.1016\/j.biopha.2018.07.110_bib0550","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","article-title":"Suppression of T H 17 differentiation and autoimmunity by a synthetic ROR ligand","volume":"472","author":"Solt","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.biopha.2018.07.110_bib0555","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/bph.13453","article-title":"Digoxin reduces atherosclerosis in apolipoprotein E\u2010deficient mice","volume":"173","author":"Shi","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2018.07.110_bib0560","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.ajpath.2018.02.005","article-title":"Imiquimod-induced psoriasis-like skin lesions do not accelerate atherosclerosis in low-density lipoprotein receptor\u2013Deficient mice","volume":"188","author":"Madsen","year":"2018","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0565","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/jcp.25778","article-title":"Therapeutic effects of curcumin in inflammatory and immune\u2010mediated diseases: A nature\u2010made jack\u2010of\u2010all\u2010trades?","volume":"233","author":"Abdollahi","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"11","key":"10.1016\/j.biopha.2018.07.110_bib0570","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1902\/jop.2016.150722","article-title":"Effect of curcumin on systemic t helper 17 cell response; gingival expressions of Interleukin-17 and retinoic acid receptor-related orphan receptor gammat; and alveolar bone loss in experimental periodontitis","volume":"87","author":"Bakir","year":"2016","journal-title":"J. Periodontol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0575","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejphar.2016.02.016","article-title":"Curcumin analog L3 alleviates diabetic atherosclerosis by multiple effects","volume":"775","author":"Zheng","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2018.07.110_bib0580","first-page":"627","article-title":"Effect of curcumin on atherosclerosis in apoE\/LDLR-double knockout mice","volume":"56","author":"Olszanecki","year":"2005","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.biopha.2018.07.110_bib0585","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2147\/COPD.S104490","article-title":"Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD","volume":"11","author":"Funamoto","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0590","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1039\/C7MD00464H","article-title":"Artificial macrocycles as IL-17A\/IL-17RA antagonists","volume":"9","author":"Wang","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.biopha.2018.07.110_bib0595","first-page":"1","article-title":"Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials","author":"Maarouf","year":"2017","journal-title":"J. Dermatolog. Treat."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0600","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13543784.2018.1412430","article-title":"Investigational drugs in clinical trials for Hidradenitis Suppurativa","volume":"27","author":"Theut Riis","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.biopha.2018.07.110_bib0605","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","article-title":"A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease","volume":"14","author":"Eich","year":"2017","journal-title":"COPD"},{"issue":"2","key":"10.1016\/j.biopha.2018.07.110_bib0610","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2018-eular.2380","article-title":"Efficacy and safety of bcd-085, a novel IL-17 inhibitor, in ankylosing spondylitis. Results of phase 2 clinical study","volume":"77","author":"Mazurov","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.07.110_bib0615","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","article-title":"IL-17 in chronic inflammation: from discovery to targeting","volume":"22","author":"Beringer","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biopha.2018.07.110_bib0620","doi-asserted-by":"crossref","DOI":"10.1002\/art.40579","article-title":"Phase 2 study of ABT\u2010122, a TNF\u2010and IL\u201017A\u2013Targeted dual variable domain immunoglobulin, in psoriatic arthritis with inadequate methotrexate response","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.110_bib0625","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jbspin.2017.04.007","article-title":"New structural formats of therapeutic antibodies for rheumatology","volume":"85","author":"Dumet","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.biopha.2018.07.110_bib0630","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13696998.2018.1431920","article-title":"The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans","volume":"21","author":"Feldman","year":"2018","journal-title":"J. Med. Econ."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218328257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218328257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:33:25Z","timestamp":1750880005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218328257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":126,"alternative-id":["S0753332218328257"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.110","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pleiotropic role of interleukin-17 in atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}